Prostate Cell News Volume 10.12 | Apr 5 2019

TOP STORY

TRIB1 Induces Macrophages to M2 Phenotype by Inhibiting IKB-Zeta in Prostate Cancer

Flow cytometry and enzyme-linked immunosorbent assay were used to examine THP-1 cells cultured in conditioned medium from prostate cancer cells overexpressing TRIB1 and showed that overexpression of TRIB1 promoted the secretion of CXCL2 and interleukin (IL)8 by PC3 cells, which increased the secretion of IL12 by THP-1 cells as well as the expression of CD163 on THP-1 cells. [Cell Signal] Abstract

(Ranked by impact factor of the journal)

Castration‐Induced Prostate Epithelial Cell Apoptosis Results from Targeted Oxidative Stress Attack of M1₁₄₂‐Macrophages

Epithelial cells showed focal DNA double‐strand breaks (DSB), 8‐oxoguanine, and protein tyrosine‐nitrosylation, fingerprints of exposure to peroxinitrite. Cultured epithelial cells induced M1‐polarization and showed focal DSB and underwent apoptosis. [J Cell Physiol] Abstract

UV Light-Inactivated HSV-1 Stimulates Natural Killer Cell-Induced Killing of Prostate Cancer Cells

Scientists demonstrated that ultraviolet light–inactivated Herpes Simplex Virus-1 (UV-HSV-1) stimulated peripheral blood mononuclear cells to lyse both androgen-sensitive and androgen-independent prostate cancer cell lines, but not the benign prostatic hyperplastic epithelial cell line, BPH-1, and was 1000–10,000-fold more potent at stimulating this killing than ultraviolet light-inactivated vesicular stomatitis virus, adenovirus, reovirus or cytomegalovirus. [J Immunother] Abstract

Radiosensitization by Enzalutamide for Human Prostate Cancer Is Mediated through the DNA Damage Repair Pathway

Enzalutamide was able to radiosensitize both androgen-dependent and androgen-independent human prostate cancer models in cell culture and xenografts in mice, as well as a treatment-resistant patient-derived xenograft. [PLoS One] Full Article

Metastatic Prostate Cancer Cells Are Highly Sensitive to 3-Bromopyruvic Acid

The authors examined how 3-bromopyruvate affects the survival and mobility of rat and human metastatic prostate cancer cell lines. [Life Sci] Abstract

Telomerase Inhibition, Telomere Shortening, and Cellular Uptake of the Perylene Derivatives PM2 and PIPER in Prostate Cancer Cells

Scientists demonstrated that the perylene derivatives, PM2 and PIPER, could suppress hTERT expression and telomerase activity in the short-term treatment of LNCaP and PC3 prostate cancer cells. [Biol Pharm Bull] Abstract

MicroRNA-302a Upregulation Mediates Chemo-Resistance in Prostate Cancer Cells

Researchers investigated whether miRNA-302a is involved in mediating chemo-resistance to paclitaxel in prostate cancer, a series of in vitro analyses were performed in paclitaxel-resistant prostate cancer PC-3PR cells and non-resistant prostate cancer PC-3 cells. [Mol Med Rep] Abstract

Oncolytic Herpes Simplex Virus and Phosphoinositide 3-Kinase Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-Like Cells

The efficacy of two different oHSVs in prostate cancer sphere-forming cells (PCSCs) was tested alone and in combination with radiation, chemotherapy, and inhibitors of PI3K, Wnt, and NOTCH in vitro, and G47Δ with the PI3K inhibitor BKM120 in a PCSC-derived tumor model in vivo. [Mol Ther Oncolytics] Abstract | Full Article

CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling

Investigators generated docetaxel-resistant PC/DX25 and DU/DX50 CRPC cells from PC-3 and DU-145 PCa cells, respectively. They investigated the mechanism behind why PC/DX25 and DU/DX50 cells exhibited higher migration and invasion ability. [Cells] Full Article | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis

The authors discuss the current evidence supporting a major role of prostate cancer (PC) stem cells (PCSCs) in PC initiation and metastasis, as well as the underlying mechanisms regulating PCSCs. [Cancers] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Early Data from Phase II Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy

Trovagene, Inc. presented early data from its ongoing Phase II study evaluating Onvansertib in combination with Zytiga^®/prednisone in patients with metastatic castration-resistant prostate cancer. [Press release from Trovagene, Inc. discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta] Press Release

ADXS-PSA In Combination With KEYTRUDA^® Prolonged Survival In Metastatic Castration-Resistant Prostate Cancer

Advaxis, Inc. announced updated data from the Phase I/II KEYNOTE-046 study in metastatic, castration-resistant prostate cancer. [Press release from Advaxis, Inc. discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta] Press Release

Anixa Biosciences Presents Cchek™ Prostate Cancer Detection Data

Anixa Biosciences, Inc. presented the latest data from its ongoing study on prostate cancer detection, utilizing Cchek™, its artificial intelligence driven cancer detection technology. [Press release from Anixa Biosciences, Inc. discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta] Press Release

Constellation Pharmaceuticals Presents Results from Phase Ib Portion of ProSTAR Clinical Trial of CPI-1205

Constellation Pharmaceuticals, Inc. presented results from the Phase Ib portion of the ProSTAR clinical trial of CPI-1205. [Press release from Constellation Pharmaceuticals, Inc. discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta] Press Release

BERG Presents Novel Mechanism Underlying BPM 31510 in Glioblastoma and Identification of Prostate and Pancreatic Cancer Biomarkers

BERG, a biopharmaceutical company that combines biology and technology to discover novel biology underlying disease, announced four presentations. [Press release from BERG (PR Newswire Association LLC) discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta] Press Release

Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg

Foresee Pharmaceuticals Co., Ltd. announced that it has submitted to the FDA a 505(b)(2) New Drug Application for LMIS 50 mg, a ready-to-use six-month depot formulation of leuprolide mesylate. The application seeks approval for the use of this product for the palliative treatment of advanced prostate cancer. [Foresee Pharmaceuticals Co., Ltd. (PR Newswire Association LLC.)] Press Release

Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial

Epic Sciences, Inc. and its research partners report the use of the company’s new circulating tumor cell homologous recombination deficiency liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer. [Epic Sciences, Inc.] Press Release

FTC Hits Predatory Scientific Publisher with a $50 Million Fine

The Federal Trade Commission (FTC) has won a summary judgement that just might cause some predatory publishers to step back from their business model. An India-based predatory publisher has been hit with a $50 million dollar judgement for deceptive business practices, along with permanent injunctions against most of the activities that made it money. [Ars Technica] Editorial

Bioethicists Concerned over Japan’s Chimera Embryo Regulations

Japanese regulators have effectively given the green light to research involving human-animal chimera embryos. Many researchers see the move to relax the rules as a welcome change, yet some are worried the revisions don’t take public concerns enough into consideration. [The Scientist] Editorial

NEW Society for Immunotherapy of Cancer (SITC) 2019
November 6-10, 2019
National Harbor, Maryland, United States

Visit our events page to see a complete list of events in the community.

NEW Research Assistant – Prostate Cancer Biology (University of Oxford)

NEW Research Fellow – Bioinformatics (University College London)

Research Investigator – Genitourinary Medical Oncology (MD Anderson Cancer Center)

Postdoctoral Fellow and PhD Student Position – Hormone Driven Cancer (Institute of Oncology Research)

Postdoctoral Position – Prostate Cancer (UT Health San Antonio)

Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital)

Faculty Position – Prostate Cancer Biology and Cancer Epigenetics (Northwestern University Feinberg School of Medicine)

Senior Computational Biologist – Molecular Oncology (Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.